SCHEMBL26824176

SCHEMBL26824176

CC(=O)OC1O[C@@H](COS(=O)(=O)C(F)(F)F)[C@H](C)[C@@H](C)[C@H]1OC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 12/20 0.42
F10 P00742 1/20 0.35
LMNA P02545 1/20 0.35
CYP2D6 P10635 1/20 0.34
THRB P10828 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CA12 O43570 11/20 0.33
CA1 P00915 10/20 0.33
CA9 Q16790 10/20 0.33
P4HB P07237 2/20 0.33
PDIA4 P13667 2/20 0.33
PDIA3 P30101 2/20 0.33
CA4 P22748 2/20 0.32
CA5A P35218 2/20 0.32
CA7 P43166 2/20 0.32
CA5B Q9Y2D0 2/20 0.32
OGA O60502 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764411 0.87 CA2 (0.55) CA2F10LMNACYP2D6THRB
SCHEMBL29709584 0.87 CA2 (0.55) CA2F10LMNACYP2D6THRB
SCHEMBL1764410 0.87 CA2 (0.55) CA2F10LMNACYP2D6THRB
SCHEMBL13640512 0.82 CA2 (0.43) CA2LMNACYP2D6THRBHSD17B10
SCHEMBL17022272 0.80 CA2 (0.33) CA2P4HBPDIA4PDIA3
SCHEMBL17195630 0.80 CA2 (0.33) CA2P4HBPDIA4PDIA3
SCHEMBL12015097 0.80 CA2 (0.33) CA2P4HBPDIA4PDIA3
SCHEMBL10028968 0.78 CYP2D6 (0.54) CA2LMNACYP2D6THRBHSD17B10
SCHEMBL16939977 0.78 CYP2D6 (0.54) CA2LMNACYP2D6THRBHSD17B10
SCHEMBL6997925 0.78 CYP2D6 (0.54) CA2LMNACYP2D6THRBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway REATA PHARMACEUTICALS, INC (US) 2023-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway HSPA2, HSP90AB2P, HSF1 CA2 3593/4885F10 3753/4885LMNA 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.